Three months after medical device firms warned investors about significant financial impacts in 2025 due to the Trump administration’s tariff policies, companies are now reducing expected charges by hundreds of millions of dollars.
Johnson & Johnson, Abbott, Boston Scientific and other top companies have told investors this earnings season that they no longer expect charges to be as dramatic as what was forecast during the prior quarter’s earnings calls.
J&J and Boston Scientific both halved their expectations for this year to approximately $200 million and $100 million, respectively. Abbott, after telling investors last quarter that they expected an impact of a few hundred million dollars, lowered their forecast to under $200 million. And Philips lowered its forecast to a range of 150 million euros to 200 million euros, about 100 million euros less than previously assumed.
While medtech companies have slashed their expected tariff charges, the effect of the Trump administration’s trade policies on businesses may be fully seen in the coming quarters, as several companies expect the majority of costs to be incurred in the second half of the year.
Other top stories this earnings season include Edwards Lifesciences losing its longtime leader for the company’s transcatheter aortic valve replacement business and J&J’s rebound in electrophysiology.
Read on for a collection of MedTech Dive’s coverage of the latest earnings season:
